Ketamine shows promise for Hard-to-Treat depression in new brain study
NCT ID NCT06668571
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 32 times
Summary
This study tests whether a single dose of intravenous ketamine can rapidly reduce depression symptoms in 30 adults with treatment-resistant depression. Researchers will measure changes in key brain chemicals (GABA and glutamate) using brain scans and blood tests. The goal is to understand how ketamine works in the brain to improve symptoms within 24 hours.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION (TRD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Conditions
Explore the condition pages connected to this study.